Dingdang Health Technology Group Ltd. submitted a Next Day Disclosure Return on 12 June 2026, confirming that the company’s issued share capital remains unchanged at 1.25 billion ordinary shares, with no treasury shares outstanding.

Between 19 May and 12 June 2026 the company bought back a cumulative 8.95 million shares that have not yet been cancelled. The daily repurchase prices ranged from HK$0.82 to HK$0.96 per share, implying a cash outlay of roughly HK$8.02 million. The shares represent about 0.71 % of current issued shares.

On 12 June 2026 alone, Dingdang Health repurchased 54,500 shares on the Stock Exchange of Hong Kong at HK$0.90–0.91 per share, spending HK$49,229.85. These shares are designated for cancellation.

Under the share-repurchase mandate approved on 28 May 2025, the company is authorised to buy back up to 131.95 million shares (5.59 % of the share base at the mandate date). To date, 73.77 million shares have been repurchased under this mandate, utilising approximately 55.9 % of the authorised limit.

In line with listing rules, the company is subject to a moratorium on new share issues until 12 July 2026.